Jessica Johnson, clinical consultant at Prime Therapeutics, shares more about common GLP-1 fraud schemes

Real-world study of GLP-1 patients continues to deliver leading insights

David Lassen, vice president of pharmacy clinical services, and Marci Chodroff, vice president and medical director at Prime Therapeutics, share more about the latest GLP-1 insights from ongoing...

Among the key findings from the study — among 4,066 members, Prime/MRx found 1 in 3 stayed on their GLP-1 and 27% took their medication as intended

Jessica Johnson, clinical consultant at Prime's Special Investigations Unit, shares how to identify fake GLP-1s

Ben Urick, senior director of health outcomes, and Landon Marshall, health outcomes research principal, share more about their educational session and research poster on GLP-1s

BioSpace: While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that myriad variables are causing patients to stop treatment

Real-world, integrated data follows-up on previous insights, analytics.